Savara (NASDAQ:SVRA) Stock Price Down 6.6%

Savara Inc (NASDAQ:SVRA) shares fell 6.6% during trading on Wednesday . The company traded as low as $4.38 and last traded at $4.38. 242,565 shares were traded during mid-day trading, a decline of 71% from the average session volume of 837,078 shares. The stock had previously closed at $4.69.

Analysts Set New Price Targets

A number of brokerages have recently commented on SVRA. Piper Sandler upped their target price on Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. JMP Securities restated a “market outperform” rating and issued a $8.00 target price on shares of Savara in a research note on Thursday, April 18th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $8.20.

Savara Stock Down 0.9 %

The company has a market cap of $609.24 million, a PE ratio of -13.36 and a beta of 0.77. The business has a 50-day simple moving average of $4.92 and a 200-day simple moving average of $4.43. The company has a quick ratio of 15.66, a current ratio of 15.66 and a debt-to-equity ratio of 0.19.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. Equities research analysts anticipate that Savara Inc will post -0.38 EPS for the current year.

Hedge Funds Weigh In On Savara

A number of hedge funds have recently bought and sold shares of the business. AJOVista LLC purchased a new position in shares of Savara in the fourth quarter valued at approximately $40,000. Principal Financial Group Inc. purchased a new position in shares of Savara in the third quarter valued at approximately $48,000. Kestra Private Wealth Services LLC purchased a new position in shares of Savara in the third quarter valued at approximately $64,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Savara in the fourth quarter valued at approximately $74,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Savara by 665.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock valued at $92,000 after acquiring an additional 16,959 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.